GlassScriptPhysician profile
Adetola A Kassim
NPI 1730295742
$26,186.73
in general payments reported to CMS, 2019-2025
19 companies · $531 in 2025
The $531 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $5,652 · 2021: $6,786 · 2022: $1,781 · 2023: $4,770 · 2024: $6,518 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,200 · Consulting Fee: $5,157 · Food and Beverage: $1,001 · Honoraria: $400 · Education: $60.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,199.79 |
| Consulting Fee | $5,157.25 |
| Food and Beverage | $1,001.06 |
| Honoraria | $400.00 |
| Education | $60.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $4,297.29 | 2021 | |
| Celgene Corporation | $3,000.00 | 2020 | |
| One Lambda, INC. | $2,973.87 | 2024 | |
| Terumo Bct, INC. | $2,770.00 | 2023 | Quantum |
| Genzyme Corporation | $2,420.00 | 2021 | |
| National Marrow Donor Program | $2,370.87 | 2022-2024 | |
| Omeros Corporation | $2,250.00 | 2020 | |
| Biolinerx USA, INC. | $2,250.00 | 2024 | Aphexda |
| Glaxosmithkline, LLC. | $1,625.00 | 2022 | |
| Pfizer INC. | $1,103.29 | 2020-2024 | |
| Astellas Pharma US INC | $268.99 | 2019-2020 | |
| Karyopharm Therapeutics INC. | $264.91 | 2021-2025 | Xpovio |
| Kite Pharma, INC. | $187.06 | 2019-2020 | |
| Genetix Biotherapeutics INC | $135.55 | 2025 | Lyfgenia |
| Iovance Biotherapeutics, INC. | $81.36 | 2025 | Amtagvi |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $71.12 | 2024 | |
| Agios Pharmaceuticals, INC. | $60.50 | 2025 | Pyrukynd |
| Janssen Biotech, INC. | $56.92 | 2025 | Carvykti, Darzalex |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adetola Kassim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.